A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy Participants
← catalyst calendarNCT07765706 · readout in 215 d
Sponsored by Insmed Incorporated (industry) · INSM — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
116estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-25 | estimated | When the study began enrolling |
| Primary completion | 2027-03-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-22 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: INS1033
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants Who Experienced at-Least One Adverse Event (AE) by Dose Level
measured Part 1: Up to Day 7; Part 2: Up to Day 21
Permalink · INSM's whole pipeline · Catalyst calendar · Every registered study · What changed